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cation was developed as an alternative to the complete wrap in
order to reduce the prevalence of post-operative symptoms such
as bloating and dysphagia. OBJECTIVE: To systematically
review the effectiveness of two different surgical techniques of
laparoscopic fundoplication (partial versus total) for the treat-
ment of GORD in adults. METHODS: A systematic search of
the literature was carried out. All randomised trials comparing
total versus partial laparoscopic fundoplication were included.
The main outcome measure was the number of patients who
were symptom free at follow-up. Other outcome measures
reviewed included clinical outcomes, PROs and QoL. In addi-
tion any long-term follow-up data were reviewed. RESULTS:
Seven randomised trials identiﬁed met the inclusion criteria for
this review. All trials included compared laparoscopic total 
fundoplication compared to partial fundoplication. Post-trial
follow-up results varied between 3–6 months and a variety of
outcome measures were reported. One study reported 12-month
results. There was no reporting on quality of life, though three
trials reported PROs. Dysphagia was more frequently reported
in patients undergoing total fundoplication compared to partial
warp RR 2.82 [95% CI: 18.4, 4.32]. No signiﬁcant differences
in post-operative bloating was found between the two surgical
techniques. There was no signiﬁcant difference in the number of
patients reporting either “good” or “excellent” outcomes
between techniques RR 0.97 [95% CI: 0.89, 1.05]. CONCLU-
SIONS: Evidence from trials supports the view that both total
and partial fundoplication are clinically effective for treating
GORD. However, long-term efﬁcacy and QoL data are needed
to choose one technique over the other.
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OBJECTIVES: To assess the cost-effectiveness of esomeprazole
(Nexium) compared to lansoprazole (Zoton FasTab) in the initial
treatment of reﬂux oesophagitis over 12 weeks from the per-
spective of the UK NHS. METHODS: A probabilistic decision
analysis model was constructed using Treeage DATATM 4.0 to
depict the sequential management of patients with unhealed
reﬂux oesophagitis. Treatment pathways were based on a pub-
lished 8-week UK healing model, however the model time
horizon was extended by an additional 4 weeks to ensure the
costs incurred by patients who remained unhealed after 8 weeks
were also included. Beta distributions for the 4 and 8 week
healing rates were calculated from a meta-analysis of the two
available head-to-head studies comparing esomeprazole 40mg (4
weeks - r = 2087, n = 2765; 8 weeks r = 342, n = 678) and lan-
soprazole 30mg (4 weeks - r = 1984, n = 2760; 8 weeks r = 347,
n = 776) in the healing of reﬂux oesophagitis. These studies used
the capsules formulation of lansoprazole. This data have been
used, as the capsule and oro-dispersible formulation are bioe-
quivalent. Triangular distributions were ﬁtted to utility values
reported by a study using the rating scale method in patients with
gastro-oesophageal reﬂux disease. Estimates of resource utilisa-
tion were obtained from a survey of UK-based clinicians, and
were multiplied by national published resource unit costs at
2003/04 prices. RESULTS: The mean cost per QALY gained with
esomeprazole and lansoprazole were £1482 and £1633 respec-
tively. Esomeprazole dominated lansoprazole (i.e. was more
effective and less expensive) in 86.8% of the 10,000 Monte
Carlo simulation patient iterations. Applying a willingness to 
pay threshold of £20,000 per QALY similar to that used by
NICE indicates that esomeprazole is cost-effective in 98.9% of
the 10,000 patient iterations. CONCLUSIONS: Esomeprazole 
is more cost-effective than the oro-dispersible formulation of 
lansoprazole in the initial treatment of reﬂux oesophagitis.
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INPATIENT COSTS OF LIVER CIRRHOSIS IN THE UNITED
STATES: A RETROSPECTIVE CLAIMS DATA ANALYSIS,
1993–2001
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OBJECTIVE: To determine the economic burden of liver cir-
rhosis, a common outcome of chronic hepatitis B, hepatitis C,
and alcoholic liver disease. METHODS: Hospital inpatient
admission records were analyzed for 1993–2001 in a health
insurance claims database (MarketScan® Database) for 3.5–5.0
million employees enrolled annually. All patients >18 years old
admitted with a primary diagnosis of cirrhosis (ICD-9-CM code
571.2 or 571.5) were included in the analysis. For each patient
identiﬁed, all admissions in a year were included except admis-
sions related to hepatocellular carcinoma, liver transplantation,
and admissions unlikely to be due to cirrhosis based on review
of all primary and secondary diagnoses for each admission. Cost
estimates were adjusted for inﬂation using the medical care com-
ponent of consumer price index and are reported in 2002 US$.
RESULTS: A total of 2073 cirrhosis patients with 4049 inpatient
admissions were identiﬁed during the 9-year period. The average
annual number of admissions per patient was 1.5 (95% conﬁ-
dence interval [CI]: 1.5–1.6); average length of hospital stay was
11.1 days (95% CI: 10.1–12.1), which decreased from 12.1 days
in 1995 to 8.1 days in 2000. The annual cost of inpatient care
per patient also decreased, from $31,244 in 1993 to $19,220 in
2000 for an average of $27,248 (95% CI: $24,247–$30,250);
86% (95% CI: 84%–87%) was for hospitalization and 7%
(95% CI: 6%–8%) for physician costs. CONCLUSIONS:
Annual cost of inpatient care for liver cirrhosis in the United
States is >$27,000 per patient hospitalized, more than twice the
average annual cost for all hospital admissions (~$12,000), and
nearly seven times the per capita annual medical care expenses
(~$4176). With >25,000 annual deaths from cirrhosis, this
causes substantial economic burden to society, and underscores
the need to prevent development of cirrhosis by preventing
hepatitis B, hepatitis C, and alcohol abuse.
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OBJECTIVES: A randomized, placebo-controlled trial demon-
strated sustained virological responses (SVR) exceeding 40% in
adult patients with PNALT/CHC using peginterferon alfa-2a
(40-kD) plus ribavirin (Peg/RBV) (Zeuzem. Hepatology 2003;
208A). We computed prognosis, costs, and cost-effectiveness of
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treatment with Peg/RBV compared with no treatment in
PNALT/CHC. METHODS: Sustained viral response (SVR) was
40% for 48-week treatment in genotype 1 and 72% for 24-week
treatment in genotype 2/3. Disease progression was modeled
based on METAVIR scores F0 to F4, followed by cirrhosis 
complications and death. Mean ﬁbrosis progression rates were
derived from literature reports of biopsy series in patients with
PNALT. The reference is a cohort of patients with mean age 45
years with PNALT and CHC, with distribution of ﬁbrosis at
baseline equal to that found in the trial. Quality of life and costs
for each health state were based on literature estimates and on
European treatment patterns. Costs in 2003 Euros and beneﬁts
were discounted at 3%. Sensitivity analyses on key clinical and
economic parameters were performed. The analysis was reported
from the perspective of a European National Health Service
(Italian setting). RESULTS: In genotype 1, Peg/RBV compared
with no treatment prolonged the time to cirrhosis by 4.8 years,
increased life years (LY) by 1.4 and quality-adjusted life years
(QALY) by 1 year. The incremental cost per QALY was 12,102€.
In genotypes 2/3, Peg/RBV prolonged the time to cirrhosis by 
8.6 years, increased LY by 2.5 and QALY by 1.8 years. The 
incremental cost per QALY was 1084€. Based on the distribu-
tion in the trial of 71% genotype 1, and 28% genotype 2/3, 
the overall CE ratio per QALY was 7419€. CONCLUSIONS:
Treatment of adults with PNALT/CHC using Peg/RBV is pro-
jected to delay time until cirrhosis, increase life expectancy, and
is cost-effective.
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OBJECTIVES: The objective of this study was to evaluate the
differences in reported levels of absenteeism and direct medical
costs between employees diagnosed with gastroesophageal 
reﬂux disease (GERD) and/or peptic ulcer disease (PUD) and a
matched-cohort with neither disease. METHODS: Data were
extracted from the MarketScan Research Database, a Health
Insurance Portability and Accountability Act compliant database
consisting of medical and prescription claims of employees
linked to the absenteeism ﬁles of their employers. Employees
with an ICD-9 code for GERD/PUD, and a matched cohort with
neither disease, were identiﬁed from January 1, 1997 to Decem-
ber 31, 2000. Demographic, absenteeism, and resource-
utilization variables were collected for all eligible subjects.
Analysis of variance was used to test the null hypothesis that the
four populations have equal means of absenteeism rates.
RESULTS: In all, 6205 employees with GERD, 2702 with PUD,
3297 with both GERD and PUD, and 42,902 matched control
subjects were identiﬁed. There was no signiﬁcant difference
between the GERD and PUD groups in health care costs, except
total prescription costs that were higher in the GERD group (p
< 0.001). Work-absenteeism rates appeared to increase in the
expected fashion, with lowest rates in the control group and
highest rates in the combined group. The magnitude of this dif-
ference was 0.3 sickness-related absence days per individual per
year between the groups with and without gastrointestinal
disease. For all-cause absences, the difference was higher with
1.5 absence days per year. Projections of this data to an average
sized Fortune 500 company of 250,000 employees would trans-
late to total direct costs of $312 million and indirect costs of
$4.75 million per year. CONCLUSIONS: Direct medical cost
and worker absenteeism, in GERD and PUD employees creates
a signiﬁcant burden on the employee community.
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OBJECTIVES: Fecal lactoferrin (FL) is a non-invasive marker,
able to distinguish between inﬂammatory and non-inﬂammatory
causes of symptoms in patients with ileal pouch-anal anastomo-
sis (IPAA). We assessed the cost-effectiveness (CE) of the FL assay
as the initial screening test for the evaluation of symptomatic
patients with IPAA. METHODS: The frequencies of pouchitis,
irritable pouch syndrome, cufﬁtis, and Crohn’s in symptomatic
patients were estimated to be 50%, 36%, 7%, and 7% respec-
tively. The FL assay has a sensitivity of 100% and a speciﬁcity
of 85% (7mg/ml threshold) to distinguish between inﬂammatory
and non-inﬂammatory causes of symptoms. Four competing
diagnostic strategies [empiric metronidazole therapy (txMTZ),
initial pouch endoscopy/biopsy (testBiop), initial FL assay then
MTZ when warranted (testFL + MTZ), and FL assay then 
pouch endoscopy/biopsy when warranted (testFL + Biop)] were
modeled in a decision tree. Response rates to all therapies were
based on current literature and expert opinion. Effectiveness
equaled the number of days out of 30 that a patient received
responsive therapy. Procedural and drug costs were estimated
from the 2003 Medicare fee schedule and current average whole-
sale price, respectively. RESULTS: In the base case, the average
cost per patient was $244 for testFL + MTZ, $251 for txMTZ,
$408 for testFL + Biop, and $431 for testBiop. All competing
strategies were more effective than test FL + MTZ, with incre-
mental effectiveness ranging from 2.0 to 0.1 days at an incre-
mental cost ranging from $8 to $1263. The incremental CE ratio
for txMTZ and testFL + MTZ of only $8 does not reﬂect unnec-
essary antibiotic exposure resulting in delayed diagnosis, adverse
effects, antimicrobial resistance, or patient preference for the
50% relative decrease in invasive endoscopic procedures. Results
were robust in multivariate sensitivity analyses. CONCLU-
SIONS: FL measurement prior to treatment with MTZ is a less
costly strategy with only a marginal decrease in effectiveness
when compared to empiric antibiotic therapy and other diag-
nostic strategies.
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OBJECTIVES: The overall aim of this investigation was to deter-
mine the best use of post-transplant immunosuppression thera-
pies, in terms of clinical and economic outcomes, for the liver
transplant population at the University of Colorado Hospital
(UCH), regardless of expected reimbursement. METHODS:
Patients were sequentially assigned to either tacrolimus (FK) or
emulsiﬁed cyclosporine (CYA) with or without mycophenolate
